eligibility_summary
Unresectable/metastatic CLDN6+ solid tumors, measurable disease, ECOG 0–1, adequate organs. Part 1: ovarian, endometrial (no sarcoma), NSCLC adeno, testicular. Part 2: ovarian, NSCLC adeno, or tumor with activity seen. Prior options exhausted. Tumor tissue/biopsy required, RT washout. Exclude: unresolved ≥G2 tox, untreated/active CNS mets, autoimmune/ILD, cardiac/ocular disease, recent surgery/steroids/vaccines/investigational tx, active HBV/HCV, HIV unless controlled, prior anti-CLDN6/TLR.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06681870 (Withdrawn before initiation). Intervention: ASP1893, an investigational, intravenous immunotherapy expected to function as a bispecific immune‑cell engager (antibody-based). Mechanism: ASP1893 is designed to bind Claudin‑6 (CLDN6) on tumor cells and a surface protein on immune effector cells, bringing them into proximity to trigger immune-mediated killing of CLDN6+ cancer cells. Targets/cells/pathways: • Tumor target: CLDN6, a tight‑junction protein aberrantly expressed on select solid tumors (ovarian, endometrial, NSCLC adenocarcinoma, testicular). • Immune target: an unspecified receptor on immune cells (e.g., on T cells or other effectors) to activate cytotoxic attack. Study design (planned): Phase 1 monotherapy, IV every 2–3 weeks, dose escalation then expansion in CLDN6‑positive tumors. Primary goals: safety, tolerability, and dose finding.